Medartis Holding AG

SWX:MED Stock Report

Market Cap: CHF 967.0m

Medartis Holding Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Matthias Schupp

Chief executive officer

CHF 868.7k

Total compensation

CEO salary percentage13.43%
CEO tenure1.3yrs
CEO ownershipn/a
Management average tenure3.8yrs
Board average tenure4.1yrs

Recent management updates

Shareholders Will Probably Not Have Any Issues With Medartis Holding AG's (VTX:MED) CEO Compensation

Apr 11
Shareholders Will Probably Not Have Any Issues With Medartis Holding AG's (VTX:MED) CEO Compensation

Recent updates

Returns At Medartis Holding (VTX:MED) Appear To Be Weighed Down

Apr 13
Returns At Medartis Holding (VTX:MED) Appear To Be Weighed Down

We Think Medartis Holding's (VTX:MED) Robust Earnings Are Conservative

Mar 26
We Think Medartis Holding's (VTX:MED) Robust Earnings Are Conservative
author-image

New CEO And Keri Touch Launch Will Accelerate US And LATAM Expansion

The strategic initiatives under new leadership in the U.S. and LATAM, including product launches and acquisitions, aim to improve revenue and market share.

These 4 Measures Indicate That Medartis Holding (VTX:MED) Is Using Debt Reasonably Well

Mar 21
These 4 Measures Indicate That Medartis Holding (VTX:MED) Is Using Debt Reasonably Well

Even With A 29% Surge, Cautious Investors Are Not Rewarding Medartis Holding AG's (VTX:MED) Performance Completely

Jan 20
Even With A 29% Surge, Cautious Investors Are Not Rewarding Medartis Holding AG's (VTX:MED) Performance Completely

A Piece Of The Puzzle Missing From Medartis Holding AG's (VTX:MED) Share Price

Nov 27
A Piece Of The Puzzle Missing From Medartis Holding AG's (VTX:MED) Share Price

Medartis Holding (VTX:MED) Has A Rock Solid Balance Sheet

Nov 09
Medartis Holding (VTX:MED) Has A Rock Solid Balance Sheet

The Strong Earnings Posted By Medartis Holding (VTX:MED) Are A Good Indication Of The Strength Of The Business

Aug 27
The Strong Earnings Posted By Medartis Holding (VTX:MED) Are A Good Indication Of The Strength Of The Business

Medartis Holding AG (VTX:MED) Doing What It Can To Lift Shares

Aug 21
Medartis Holding AG (VTX:MED) Doing What It Can To Lift Shares

When Should You Buy Medartis Holding AG (VTX:MED)?

May 10
When Should You Buy Medartis Holding AG (VTX:MED)?

Shareholders Will Probably Not Have Any Issues With Medartis Holding AG's (VTX:MED) CEO Compensation

Apr 11
Shareholders Will Probably Not Have Any Issues With Medartis Holding AG's (VTX:MED) CEO Compensation

The Returns On Capital At Medartis Holding (VTX:MED) Don't Inspire Confidence

Feb 14
The Returns On Capital At Medartis Holding (VTX:MED) Don't Inspire Confidence

Medartis Holding (VTX:MED) Will Be Hoping To Turn Its Returns On Capital Around

Oct 24
Medartis Holding (VTX:MED) Will Be Hoping To Turn Its Returns On Capital Around

Is Medartis Holding (VTX:MED) A Risky Investment?

Oct 03
Is Medartis Holding (VTX:MED) A Risky Investment?

Is Medartis Holding AG (VTX:MED) Expensive For A Reason? A Look At Its Intrinsic Value

Sep 06
Is Medartis Holding AG (VTX:MED) Expensive For A Reason? A Look At Its Intrinsic Value

Market Still Lacking Some Conviction On Medartis Holding AG (VTX:MED)

Jun 21
Market Still Lacking Some Conviction On Medartis Holding AG (VTX:MED)

Medartis Holding (VTX:MED) May Have Issues Allocating Its Capital

Jan 31
Medartis Holding (VTX:MED) May Have Issues Allocating Its Capital

Why Medartis Holding AG (VTX:MED) Could Be Worth Watching

Oct 30
Why Medartis Holding AG (VTX:MED) Could Be Worth Watching

These Analysts Think Medartis Holding AG's (VTX:MED) Sales Are Under Threat

Sep 07
These Analysts Think Medartis Holding AG's (VTX:MED) Sales Are Under Threat

When Should You Buy Medartis Holding AG (VTX:MED)?

Jul 29
When Should You Buy Medartis Holding AG (VTX:MED)?

Medartis Holding (VTX:MED) Could Be Struggling To Allocate Capital

May 06
Medartis Holding (VTX:MED) Could Be Struggling To Allocate Capital

At CHF123, Is It Time To Put Medartis Holding AG (VTX:MED) On Your Watch List?

Feb 08
At CHF123, Is It Time To Put Medartis Holding AG (VTX:MED) On Your Watch List?

Medartis Holding (VTX:MED) Will Be Hoping To Turn Its Returns On Capital Around

Jan 18
Medartis Holding (VTX:MED) Will Be Hoping To Turn Its Returns On Capital Around

We Think Medartis Holding (VTX:MED) Can Stay On Top Of Its Debt

Nov 10
We Think Medartis Holding (VTX:MED) Can Stay On Top Of Its Debt

Medartis Holding (VTX:MED) Could Be Struggling To Allocate Capital

Sep 29
Medartis Holding (VTX:MED) Could Be Struggling To Allocate Capital

Some Investors May Be Worried About Medartis Holding's (VTX:MED) Returns On Capital

Jun 08
Some Investors May Be Worried About Medartis Holding's (VTX:MED) Returns On Capital

How Much Of Medartis Holding AG (VTX:MED) Do Insiders Own?

Mar 16
How Much Of Medartis Holding AG (VTX:MED) Do Insiders Own?

We're Watching These Trends At Medartis Holding (VTX:MED)

Feb 09
We're Watching These Trends At Medartis Holding (VTX:MED)

Medartis Holding (VTX:MED) Shareholders Have Enjoyed A 10% Share Price Gain

Jan 04
Medartis Holding (VTX:MED) Shareholders Have Enjoyed A 10% Share Price Gain

What Type Of Shareholders Own The Most Number of Medartis Holding AG (VTX:MED) Shares?

Nov 19
What Type Of Shareholders Own The Most Number of Medartis Holding AG (VTX:MED) Shares?

CEO Compensation Analysis

How has Matthias Schupp's remuneration changed compared to Medartis Holding's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024CHF 869kCHF 117k

CHF 4m

Compensation vs Market: Matthias's total compensation ($USD1.06M) is about average for companies of similar size in the Swiss market ($USD1.31M).

Compensation vs Earnings: Insufficient data to compare Matthias's compensation with company performance.

CEO

Matthias Schupp (60 yo)

1.3yrs
Tenure
CHF 868,699
Compensation

Mr. Matthias Schupp is CEO & Member of the Executive Management Board of Medartis Holding AG from 2024. He had been Chief Executive Officer of Neodent at Straumann Holding AG since 2015 until 2024 and serv...

Leadership Team

NamePositionTenureCompensationOwnership
Matthias Schupp
CEO & Member of the Executive Management Board1.3yrsCHF 868.70kno data
Thomas Straumann
Founder & Vice Chairman27.3yrsCHF 292.06k45.37%
CHF 438.7m
Dirk Kirsten
CFO & Member of the Executive Management Board4.2yrsno data0.032%
CHF 309.7k
Mareike Loch
President of EMEA & Member of Executive Management Board4.8yrsno data0.059%
CHF 566.6k
Manuel Schaer
CTO & Member of the Executive Board4.5yrsno data0.019%
CHF 180.0k
Mario Casa
COO & Member of Management Board3.3yrsno data0.0029%
CHF 28.4k
Inge Maes
Chief Human Resources Officer & Executive Management Board Member1.3yrsno datano data
David Thoni
President of US & Member of Executive Management Boardless than a yearno datano data
Anisha Wharton
Head of Regulatory Affairs4.2yrsno datano data
3.8yrs
Average Tenure
55yo
Average Age

Experienced Management: MED's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Thomas Straumann
Founder & Vice Chairman27.3yrsCHF 292.06k45.37%
CHF 438.7m
Damien Tappy
Independent Non-Executive Director7.3yrsCHF 171.65k0.20%
CHF 2.0m
Marco Gadola
Independent Chairman5.1yrsCHF 535.28k0.071%
CHF 689.6k
Ciro Roemer
Independent Director3.1yrsCHF 150.00k0.011%
CHF 102.1k
Willi Miesch
Independent Non Executive Director15.3yrsCHF 161.73k4.98%
CHF 48.2m
Martha Shadan
Independent Non-Executive Director1.1yrsCHF 100.00kno data
Jennifer Dean
Independent Non-Executive Director1.1yrsCHF 107.83kno data
Nadia Schmidt
Independent Director3.1yrsCHF 167.12k0.0079%
CHF 76.6k
4.1yrs
Average Tenure
60.5yo
Average Age

Experienced Board: MED's board of directors are considered experienced (4.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/25 02:53
End of Day Share Price 2025/05/23 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medartis Holding AG is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eric Le BerrigaudBryan Garnier & Co
Maria Vara FernándezBryan Garnier & Co
Hugo SolvetBryan Garnier & Co